Project Grant R01HL183591
Award Date 8/1/26
Completion Date 4/30/30
Dollars Obligated $744K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
San Francisco, CA 94143, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded The Regents of the University of California, San Francisco $778,504 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate molecular mechanisms controlling lung capillary speciation, plasticity, and function during early postnatal development. The research examines how distinct subtypes of lung capillary endothelial cells—CAP1 and CAP2—contribute to alveolar formation and repair after injury during...
- The National Heart, Lung, and Blood Institute awarded The Regents of the University of California, San Francisco $1,097,760 on February 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to fund a Project Grant (R35HL183538) investigating mechanisms of age-related pulmonary fibrosis and lung regeneration. The research program addresses idiopathic pulmonary fibrosis (IPF), a progressive disease affecting approximately 200,000 patients annually in the United States with...
- The National Heart, Lung, and Blood Institute awarded The Trustees of Columbia University in the City of New York $1,151,498 on March 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support research on lung epithelial development and regeneration. The research aims to restore epithelial integrity and prevent end-stage lung diseases such as idiopathic pulmonary fibrosis by understanding how the lung epithelium develops in embryos and regenerates following injury....
- The National Heart, Lung, and Blood Institute awarded The Regents of the University of California, San Francisco $731,287 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate airway epithelial cell reprogramming mechanisms in chronic lung allograft dysfunction. The research will test whether mTOR signaling drives chronic lung allograft dysfunction through airway epithelial cell reprogramming and examine mTOR as a predictive biomarker of allograft...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded The Regents of the University of California, San Francisco (UCSF) $297,806 on September 30, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of the senescence marker P16INK4A in alveolar epithelial stem cells during injury-triggered differentiation. The research examines how alveolar type 2 cells (AT2s), which serve as lung stem cells, differentiate into alveolar type 1 cells and how the...
- The National Heart, Lung, and Blood Institute, part of the Department of Health and Human Services, awarded $795,464 to The Regents of the University of California, San Francisco on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds research into adaptive-like natural killer cells in pulmonary cytomegalovirus reactivation. The project investigates whether local cytomegalovirus-specific natural killer cell immune responses in the lungs potentiate...
- The National Heart, Lung, and Blood Institute awarded The Regents of the University of California, San Francisco $1,559,572 on June 17, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds research into the multiciliation cycle, a variant cell cycle mechanism that coordinates centriole biogenesis and ciliogenesis in multiciliated cells lining the mammalian airway. Multiciliated cells defend the lungs from inhaled pathogens and particulates but require...
- The National Heart, Lung, and Blood Institute awarded the University of Southern California $1,263,067 on September 10, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate transitional alveolar epithelial cells in normal lung development. The research, led by Principal Investigator Parviz Minoo, examines intermediate and transitional alveolar epithelial cells (AEC) in neonatal lungs undergoing alveologenesis, with particular focus on their regenerative...
- The National Heart, Lung, and Blood Institute awarded The Regents of the University of California, San Francisco $163,836 on July 8, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct basic research into the cellular and molecular pathways that drive pulmonary silicosis. The research dissects bidirectional signaling networks between fibroblasts and macrophages in silica-induced granulomatous lung injury. Preliminary single-cell RNA sequencing identified...
- The National Heart, Lung, and Blood Institute awarded The Regents of the University of California, San Francisco $174,744 on June 2, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of the phosphatase SHP1 in modulating acute lung injury and acute respiratory distress syndrome. The research focuses on SHP1-dependent regulation of neutrophil activation and its protective effects against hyperinflammation and pulmonary hemorrhage in acute lung...